Helius Medical Technologies, Inc. Appoints Frederick Fantazzia as Vice President of Sales & Marketing, North America
June 02 2021 - 7:05AM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced the appointment of Frederick Fantazzia to
the position of Vice President of Sales & Marketing, North
America, effective June 1, 2021.
“Fred is a dynamic leader with 16 years of sales
and marketing experience in the field of neuromodulation, and a
specific focus on developing the market for new neuromodulation
technologies by building and leading high-quality sales team to
raise awareness and facilitate commercial adoption,” said Dane
Andreeff, Interim President and Chief Executive Officer of Helius.
“We are pleased to welcome him to our leadership team and look
forward to his contributions as we continue our
pre-commercialization initiatives and prepare to commercialize our
PoNS Treatment in the United States.”
“I believe Helius is a rising star in the
development of innovative neuromodulation technologies to treat
conditions related to the effects of neurological disease and
trauma,” said Mr. Fantazzia. “With the Company’s PoNS device now
authorized for sale in the U.S., I am excited to join the team at
this important inflection point. I look forward to developing the
market for PoNS Treatment and bringing it to U.S. patients
suffering from the effects of multiple sclerosis.”
Prior to joining Helius, Mr. Fantazzia worked for
LivaNova, PLC (Nasdaq: LIVN), a global medical technology company
that designs, develops, manufactures and sells innovative
therapeutic solutions in the fields of neuromodulation and
cardiovascular disease, from 2016 until 2021. He most recently
served as Vice President of North America Sales and Marketing for
LivaNova’s Epilepsy business, where he managed all aspects related
to its commercialization of a neuromodulation technology for the
treatment of drug-resistant epilepsy. During his time with
LivaNova/Cyberonics Inc., Mr. Fantazzia also served as Vice
President of Global Sales and Marketing for its Neuromodulation
segment from 2015 to 2016 and Vice President of U.S. Sales from
2016 to 2018.
Prior to the merger between Sorin S.p.A. and
Cyberonics Inc., which combined to form LivaNova in 2015, Mr.
Fantazzia worked for Cyberonics Inc. (Nasdaq: CYBX) a medical
device company with core expertise in neuromodulation. He joined
the company as a Regional Sales Manager in 2005, and subsequently
held a series of positions of increasing responsibility,
culminating in his promotion to Vice President of Global Sales and
Marketing for Neuromodulation in 2015.
Mr. Fantazzia holds a B.S. in Business
Administration from Villanova University.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech company
focused on neurological wellness. The Company’s purpose is to
develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS™). For more information,
visit www.heliusmedical.com.
About the PoNS™ Device and PoNS
Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is
an innovative non-surgical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to provide treatment of gait deficit. The PoNS device is
indicated for use in the United States as a short term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. It is authorized for sale in Canada as a
class II, non-implantable, medical device intended as a short term
treatment (14 weeks) of gait deficit due to mild and moderate
symptoms from MS, and chronic balance deficit due to
mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used
in conjunction with physical therapy. The PoNS™ is an
investigational medical device in the European Union (“EU”) and
Australia (“AUS”). It is currently under premarket review by the
AUS Therapeutic Goods Administration.
Investor Relations Contact:
Westwicke on behalf of Helius Medical Technologies,
Inc.Jack Powell, Vice
Presidentinvestorrelations@heliusmedical.com
Cautionary Disclaimer
Statement:
Certain statements in this news release are not
based on historical facts and constitute forward-looking statements
or forward-looking information within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. All statements other than statements of historical
fact included in this news release are forward-looking statements
that involve risks and uncertainties. Forward-looking statements
are often identified by terms such as “believe,” “continue,” “look
forward,” “will,” “committed to,” “goal,” “expect,” “remain,”
“hope” and similar expressions. Such forward-looking statements
include, among others, statements regarding the Company’s future
growth and operational progress, the next phase of the Company’s
market development activities, clinical and regulatory development
plans for the PoNS device, the timing and success of the Company’s
commercialization efforts in the United States, and the ability for
the Company to develop the market for PoNS Treatment and bringing
it to U.S. patients suffering from the effects of multiple
sclerosis.
These statements involve substantial known and
unknown risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those expressed or
implied by such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include , uncertainties regarding the Company’s capital
requirements to achieve its business objectives, the impact of the
COVID-19 pandemic, the Company’s ability to train physical
therapists in the supervision of the use of the PoNS Treatment, the
Company’s ability to secure contracts with rehabilitation clinics,
the Company’s ability to obtain national Medicare coverage and to
obtain a reimbursement code so that the PoNS device is covered by
Medicare and Medicaid, the Company’s ability to build internal
commercial infrastructure, market awareness of the PoNS device,
future clinical trials and the clinical development process,
manufacturing and supply chain risks, potential changes to the MCIT
program, the product development process and FDA regulatory
submission review and approval process, other development
activities, ongoing government regulation, and other risks detailed
from time to time in the filings made by the Company with
securities regulators, including the risks and uncertainties
described in the “Risk Factors” sections of the Company’s Annual
Report on Form 10-K for the year ended December 31, 2020 and its
other filings with the United States Securities and Exchange
Commission and the Canadian securities regulators, which can be
obtained from either at www.sec.gov or www.sedar.com. The
reader is cautioned not to place undue reliance on any
forward-looking statement. The forward-looking statements contained
in this news release are made as of the date of this news release
and the Company assumes no obligation to update any forward-looking
statement or to update the reasons why actual results could differ
from such statements except to the extent required by law.
The Toronto Stock Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of the
content of this news release.
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Sep 2023 to Sep 2024